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Abstract Introduction 
Besides the psychoactive A%tetrahydrocannabinol (THC), hashish 
and marijuana as well as cannabis-based medicine extracts contain 
varying amounts of cannabidiol (CBD) and of the degradation 
product cannabinol (CBN). The additional determination of these 
compounds is interesting from forensic and medical points of view 
because it can be used for further proof of cannabis exposure and 
because CBD is known to modify the effects of THC. Therefore, a 
method for the simultaneous quantitative determination of THC, its 
metabolites 11-hydroxy-A%tetrahydrocannabinol (11-OH-THC) and 
11-nor-9-carboxy-A%tetrahydrocannabinol (THC-COOH), CBD 
and CBN from plasma was developed. The method was based on 
automatic solid-phase extraction with C18 ec columns, 
derivatization with N,O-bistrimethylsilyltrifluoroacetamide 
(BSTFA), and gas chromatography-electron impact ionization-mass 
spectrometry (GC-EI-MS) with deuterated standards. The limits of 
detection were between 0.15 and 0.29 ng/mL for THC, 11-OH- 
THC, THC-COOH, and CBD and 1.1 ng/mL for CBN. The method 
was applied in a prospective pharmacokinetic study after single 
oral administration of 10 mg THC alone or together with 5.4 mg 
CBD in cannabis extract. The maximum plasma concentrations 
after cannabis extract administration ranged between 1.2 and 
10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 
4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for 
THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD. 
The peak concentrations (mean values) of THC, 11-OH-THC, 
THC-COOH, and CBD were observed at 56, 82, 115, and 60 rain, 
respectively, after intake. CBN was not detected. Caused by the 
strong first-pass metabolism, the concentrations of the metabolites 
were increased during the first hours after drug administration 
when compared to literature data for smoking. Therefore, the 
concentration ratio 11-OH-THC/THC was discussed as a criterion 
for distinguishing oral from inhalative cannabis consumption. 
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There is an increasing interest in analytical data of cannabi- 
noids in human samples from a forensic as well as from a clin- 
ical point of view. The growing use of this drug and the 
enduring discussion about its legalization in several countries 
require more information about its pharmacokinetic behaviour 
as a prerequisite for the development of traffic safety standards 
and for evaluation of concentrations i  traffic cases and other 
offences (1). In the same way, more data about concentra- 
tion/effect relationships are needed in context with the intro- 
duction of Ag-tetrahydrocannabino[ (THC) as a remedy with 
anti-emetic, appetite-inducing, muscle-relaxant, analgesic, anti- 
glaucoma, nti-asthmatic, and anti-epileptic ndications (2). 
The pharmacokinetics of cannabinoids were recently re- 
viewed by Grotenhermen (3). The course of the plasma con- 
centrations was measured after smoking (4-14), oral intake 
(4,14-18), and intravenous injection (4,7,8,14-16,18,19) of 
THC or cannabis products by several authors. In most studies, 
the analysis is limited to THC and its metabolites 11-hydroxy- 
Ag-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy- 
Ag-tetrahydrocannabinol (THC-COOH). However, after 
consumption f marijuana or hashish, the main constituents of 
cannabis cannabidiol (CBD) and cannabinol (CBN) should also 
be considered. 
After THC, CBD is the most abundant cannabinoid in 
cannabis plants. According to newer esults (20,21), the car- 
boxylated precursors in the biosynthesis ofCBD and THC are 
both directly derived from cannabigerolic a id by different en- 
zymes. The existence of the postulated enzyme CBD-cyclase cat- 
alyzing the synthesis of THC via CBD has not been 
experimentally confirmed. The CBDfrHC ratio is mainly de- 
pendent on the genetic background of the individual plant. 
With respect to the cannabinoid composition, the cannabis 
782 Reproduction (photocopying) of editoria[ content of this journal is prohibited without publisher's permission. 
Journal of Analytical Toxicology, Vol. 29, November/December 2005 
plants can be divided into a chemotype with a high THC and a 
low CBD content, an intermediate chemotype with a preva- 
lent CBD content and THC present at various concentrations, 
and a chemotype with a particularly low THC content. The av- 
erage concentrations n more than 30,000 marijuana prepara- 
tions confiscated in the U.S. between 1980 and 97were 3.1% 
THC and only 0.3% CBD (22). However, cannabis-based 
medicine xtracts and clinical-grade cannabis contain high 
quantities of CBD, which frequently equal the percentage of
THC (23). CBD modifies the effects of THC and is described to
have anti-anxiety effects (24) and anti-psychotic benefits (25) 
and to inhibit he CYP-P450 mediated conversion of THC to 11- 
OH-THC (26). Furthermore, anticonvulsive and anti-inflam- 
matory effects were reported (27). 
More than 30 metabolites ofCBD were identified in urine, 
with the hydroxylation f the 7-methyl group and subsequent 
oxidation to the corresponding carboxylic acid as the main 
metabolic route in analogy to THC (14,28,29). The time course 
of the CBD concentration in plasma after oral application was 
measured inthree studies (8,14,30). Itwas found that CBD is 
eliminated in an at least two-phase kinetic with aterminal half 
life of 31 + 4 h after smoking (8). The formation of THC from 
CBD neither occurs by heat during smoking (29) nor by human 
metabolism. 
CBN is not a biosynthetic product of cannabis plants but is 
formed by air oxidation from THC during preparation of 
hashish or during longer storage of cannabis products (31). Its 
average content was 0.3% in marijuana nd 1.7% in hashish 
samples (22). No psychoactive effects of this compound were 
noted, but it may modify the effects and the metabolization f 
THC (30). Pharmacokinetic data of CBN are known from 
smoking, oral application, and infusion (14,32). CBN is not 
formed from THC in human metabolism. Its main metabolic 
pathway isthe hydroxylation fthe C-atom 7 and subsequent 
transformation to the corresponding carboxylic acid (14,33). 
Because of these properties, the determination f CBD and 
CBN in addition to THC and its metabolites after consumption 
of cannabis products is interesting from a forensic point of 
view and in clinical studies. The methods described inliterature 
for this purpose did either not involve all five substances in
one run (33-41) or were not sufficiently sensitive (42). In this 
paper, we describe the development a d optimization f a gas 
chromatography-mass spectrometry (GC-MS) method for the 
simultaneous and sensitive analysis of THC, 11-OH-THC, THC- 
COOH, CBD, and CBN from 1 mL plasma. The method was 
used in a prospective clinical study in which the concentration 
versus time profiles ofthe compounds after oral application of 
10 mg THC alone and in cannabis extract were measured. Some 
examples ofthis application are shown in this paper. 
Materials and Methods 
Volunteers and plasma samples 
In the prospective, double-blind, placebo-controlled cross- 
over study each of 24 volunteers (age 18 to 45 years) were ad- 
ministered four capsules with either cannabis extract (2.5 mg 
THC and 1.35 mg CBD per capsule), THC (2.5 mg per cap- 
sule), or placebo in fasting state (last meal at least 8 h before ap- 
plication) that lasted for 4 h after drug intake. Between the 
three applications, there was a one-week wash-out phase. Before 
each administration, the urine of the volunteers was controlled 
by EMIT for cannabinoids and other drugs or drug metabolites. 
Blood samples were taken 30 rain before and 30, 60, 120, 180, 
240, 360, 540, and 1440 min after drug administration with 
EDTA as anticoagulant. The samples were centrifuged wi hin 15 
min, and the plasma (2-2.5 mL) was separated and frozen at 
-30~ until investigation. 
This study was approved by the local Ethics Committee of the 
University Hospital Charit~ of the Humboldt-University Berlin, 
and written informed consent was obtained from each volunteer. 
Reference substances and reagents 
Standard solutions (0.1 mg/mL in methanol) of THC, 11- 
OH-THC, and THC-COOH as well as of the corresponding 
deuterated compounds (THC-d3, 11-OH-THC-d3, and THC- 
COOH-d3) were purchased from Promochem (Wesel, Germany). 
CBD and CBN (1 mg/mL in methanol) as well as the reagents 
for silylation H,O-bistrimethylsilyltrifluoroacetamide (BSTFA, 
with 1% trimethylchlorosilane), methyltrimethylsilyltrifluo- 
roacetamide (MSTFA, with 1% trimethylchlorosilane), tri-i- 
propylchlorosilane (TIPS-CI), methyl-tert-butyldimethyl- 
silyltrifluoroacetamide (MTBSTFA), and dimethylphenylchlor- 
silan were obtained from Sigma-Aldrich (Steinheim, Germany). 
Trimethylsulfonium hydroxide (TMSH, 0.2M in methanol) and 
tetramethyloxonium tetrafluoroborate (M%OBF4) were pur- 
chased from Macherey & Nagel (D~ren, Germany) and from 
Merck Eurolab (Darmstadt, Germany), respectively. All sol- 
vents and other eagents were obtained in analytical grade pu- 
rity from Merck (Darmstadt, Germany). 
Instruments 
The GC-MS measurements were performed with a gas chro- 
matograph 6890, a mass selective det ctor 5973, and an au- 
tosampler 7673 (Agilent Technologies GmbH, Waldbronn, 
Germany). 
The solid-phase extraction (SPE) was automatically carried 
out with a RapidTrace extractor (Zymark, Rfisselsheim, Ger- 
many). All steps of column conditioning, sample extraction, 
washing, and drug elution were monitored by the software 
RapidTrace Workstation, Version 1.20. For liquid-liquid ex- 
traction, a thermomixer 5433 (Eppendorf, Hamburg, Germany) 
was used. The solvents were removed by an evaporator fthe 
firm Liebisch (Bielefeld, Germany). 
SPE and derivatization 
Each sample was analyzed twice. After optimization, the fol- 
lowing procedure was used: 10 IJL of a solution of the internal 
standards THC-d3, 11-OH-THC-d3, and THC-COOH-d3 (each 
1 pg/mL in n-propanol) and I mL 0.1M acetate buffer pH 4.0 
were added to 1 mL plasma in a 10-mL vial and thoroughly 
mixed. Small amounts of precipitate were removed by cen- 
trifugation, and the supernatant was transferred into a 4-mL 
sample vial of the RapidTrace. 
The extraction was carried out with Chromabond C18 ec 
columns (Macherey-Nagel, Dfiren, Germany, 200 mg extraction 
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material, 3 mL volume). The columns were conditioned with 6 
mL H20 (0.1 mL/s), 6 mL methanol (0.03 mL/s), and 2 mL ac- 
etate buffer pH4.0 (0.1 mL/s). The extraction of the sample was 
carried out with a flow rate of0.02 mL/s. After loading, the 
columns were washed with i mL 0.1M acetic acid in H20 (0.05 
mL/s) and 2 mL 40% acetonitrile/H20 (0.05 mL/s) and dried for 
2 min in a nitrogen stream. Finally, the drugs were eluted with 
1.8 mL acetonitrile (0.02 mL/s). 
The solvent was evaporated at 40~ in a nitrogen stream, and 
the residue was derivatized with 20IJL BSTFA for 30 min at 
room temperature. Themixture was transferred into a 100-1JL 
vial, and 2 IJL was injected for GC-MS analysis. 
GC-MS measurements 
The GC separation was carried out with a capillary column 
HP 5 MS (95% dimethylsiloxan, 5% diphenylsiloxan, 30 m x 
0.25 mm x 0.25 IJm) with the following temperature program: 
2 rain at 130~ 20~ up to 300~ and 5 min at 300~ 
The temperatures of the injector, the interface, the ion source, 
and the quadrupole were 290~ 310~ 260~ and 106~ 
respectively. The injection mode was spitless, and the injection 
volume was 2 lJL. 
The retention times under these conditions and the m/z 
values chosen for the detection of the trimethylsilyl deriva- 
tives in the selected ion monitoring mode (SIM, five time win- 
dows) are given in Table I. A typical chromatogram of a plasma 
sample spiked with each 5 ng/mL of the five analytes and 10 
ng/mL of the deuterated standards is shown in Figure 1. For 
confirmation of the peak identity, the exact retention times 
and the peak-area ratios of the three m/z traces per substance 
were controlled, and those for THC, 11-OH-THC, and THC- 
COOH compared with those of the deuterated standards. 
Calibration and validation f the method 
The extraction recoveries of the sample preparation 
were calculated as the quotient of the GC-MS peak areas 
obtained from spiked plasma samples fter extraction and 
by direct injection of the same substance amount. In this 
case, the internal standards were added after the extraction 
in order to correct for fluctuations of the 
GC-MS sensitivity. The mean recoveries ob-
tained from two extraction experiments are ,6 
given in Table II. 
14 The calibration and the validation of the 
method were performed according to the rec- '9 1 
ommendations of the program Valistat (43). X 1 
Plasma samples were spiked with 0.0, 0.25, r 
0.5, 1.0, 1.5, 2.0, 5.0, and 10.0 ng/mL of the five 
analytes. For THC-COOH, 25 ng/mL and 50 "~ 
ng/mL were additionally included because of ,,r 
the expected higher concentrations. These 
samples were extracted, derivatized, and mea- 
sured by GC-MS as described previously. Each 
concentration was prepared and analyzed six 
times. The peak areas of the quantifier ion 
traces of THC, 11-OH-THC, and THC-COOH 
(Table I) were related to those of the corre- 
sponding deuterated internal standards. 11- 
OH-THC-d3 (m/z 374) was also used as internal standard for 
CBD and CBN. The calibration curves were linear with zero n-
tersections for all five compounds. The correlation coefficients 
and the limits of detection (LOD) and quantification (LOQ) de- 
termined from these data according to the validation program 
Valistat (43) are given in Table II. In this statistical program, the 
standard deviation of the calibration curve is used for calcula- 
tion of LOD and LOQ. About the same values were estimated 
from the 3-fold and the 10-fold standard deviation of the base- 
line noise. The LOD and LOQ estimated on this basis from real 
samples of the pharmacokinetic study were, in manycases, 
below those given in Table II. 
For determination f the interday reproducibility of the 
method, spiked serum samples containing 10 ng/mL of the 
five substances were analyzed in each of the 40 measurement 
series of the study. The apparent recoveries and tandard evi- 
ations calculated from these measurements are also given in 
Table II. Furthermore, all plasma samples of th  clinical study 
were measured twice. The average deviation of the concentra- 
tions from the mean of both concentrations was between 1.8 
and 3.9% (Table II). 
Table I. Retention Times, Time Windows, and Mass-to- 
Charge Ratio Values for the Detection of Trimethylsilyl 
Derivatives of Cannabinoids in the SIM Mode 
m/z Registered Retention Time 
Compound in SIMMode* Time(min)+ Window (min) 
CBD-2TMS 319, 390, 458 9.45 9.10-9.80 
THC-TMS-d3 306, 374, 389 9.97 9.80-10.15 
THC-TMS 303, 371,386 9.98 9.80-10.15 
CBN-TMS 310, 367, 382 10.36 10.15-10.60 
11-OH-THC-2TMS-d3 374, 462,477 10.98 10.60-11.20 
11-OH-THC-2TMS 371,459, 474 10.99 10.60-11.20 
THC-COOH-2TMS-d ~ 374, 476,491 11.65 11.20-12.00 
THC-COOH-2TMS 371,473,488 11.66 11.20-12.00 
* Quant i f i ca t ion  ions  are  [ )o ld .  
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Figure 1. GC-MS-SIM chromatogram of a plasma sample spiked with each 5 ng/mL of THC, 
11-OH-THC, THC-COOH, CBD, and CBN and 10 ng/mL of the internal standards THC-d3, 
11 -OH-THC-d 3, and THC-COOH-d~. 
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Results and Discussion 
The analysis of plasma samples for cannabinoids byGC-MS is 
daily routine in forensic toxicological laboratories. Normally, 
Table II. Data of the Calibration, Recoveries of Extraction, LOD and LOQ, 
Apparent Recoveries, and Reproducibility of the Method for Determination 
of Cannabinoids* 
11-THC- THC- 
THC OH COOH CBD CBN 
F 0.958 1.084 1.047 0.00564 
R 2 0.9996 0.9997 0.9988 0.9977 
Recovery of extraction (%) 50 95 85 90 
LOD (ng/mL) 0,24 0,15 0.26 0.29 
LOQ (ng/mL) 0.80 0.51 0.88 0.95 
Apparent recovery (n = 40) (%)t 101 99 95 104 
Standard deviation (n = 40) (%) 2.8 1.9 3.7 2.9 
Average deviation from mean in 2.9 1.8 3.0 3.9 
double determination (n = 480) (%) 
* Abbreviations: F = calibration factor (  = F x peak-area ratio analyt/internal standard), R = correlation 
coefficient, LOD = limit of detection, LOQ = limit of quantification. 
t The terms "recovery" and "apparent recovery" were used according to the IUPAC recommendation 
published in (48). The apparent recoveries (%) are amount calculated from the calibration curve/spiked 
amount x 100. 
* CBN was not detected in the samples of the clinical study. 
the investigations are limited to THC, 11-OH-THC, and THC- 
COOH and detection limits of 1 ng/mL are sufficient. However, 
in the present study, CBD and CBN had to be included, and a de- 
tection limit below 0.5 ng/mL was necessary inorder to follow 
up the concentrations for a sufficiently long 
time after administration. Only 2-2.5 mL 
plasma per sample were available. Therefore, 
the method, particularly the extraction and the 
derivatization, had to be adapted to these re- 
quirements before application t  the study. 
Table Iii. Comparison of Different Derivatization 
Methods for Cannabinoids* 
11-OH- THC- 
Reagent/Method* CBD THC CBN THC COOH 
No derivatization + + + - - 
Metbylation (49) 
Mel/rBAH in DMSO - + + + + 
Mel/TBAH in - + + - - 
DMSO + TMSH 
Mel/NaOH in ACN + + + + + 
in DMF + + + - - 
in DMSO - + + - - 
Mel/K2CO3 in DMF + + + - - 
Mel/LiAIH4 in DMF . . . . .  
TMSH + + + + + 
[Me30][BF 4] in DCM . . . .  
Alkylation + acylation (50) 
PFPNPFPOH + + + + + 
Silylation (33,45) 
BSTFA + + + + + 
MTBSTFA + + + + + 
TIPS-NEt2 + + + + - 
Me2PhSi-NEt 2 + + + - 
Me2iPrSi-NEt2 + + + + + 
* GC-MS-detection in SCAN after treatment of 100 ng standard: -, not detected; +, 
detected; ACN, acetonitrile; 8STFA, N,O-bistrimethy[silyltrifluoroacetamide; 
DMF, dimetbylformamide; DMSO, dimethylsulfoxide; Mel, methyl iodide; 
Me2PhSi-NEt2, N-(dimethylphenylsilyl)-N,N-diethylamine; Me2iPrSi-NEt2, N- 
(dimethyl-i-propylsilyl)-N,N-diethylamine; MTBSTFA, melhyl-tert- 
butyldimethylsilyltrifluoroacetamide; PFPA, pentafluoropropionic anhydride; 
PFPOH, pentafluoropropanol; TBAH, tetrabutylammonium hydroxide, TIPS-NEt2, 
tri-i-propylsilyl-diethylamine; and TMSH, trimethylsulfonium hydroxide. 
Development of the analytical method 
0.0045 Derivatization. At first, a suitable derivati- 
0.9968 zation reaction had to be found. This was also 
43 a prerequisite for the extraction optimization. 
1.1 For this purpose, different derivatization pos- 
3.9 sibilities were compared. Mixtures of 100 ng of 
101 each of the five compounds were prepared from 7.7 
_, the standard solutions by evaporation f the 
solvent, and the reagents were applied to the 
residues. The products were analyzed by 
GC-MS in SCAN mode. In those cases in which 
all five compounds were clearly detected an
well separated, the experiments were repeated 
with 5, 2, 1, and 0.5 ng of the substances, and 
the measurements were performed in SIM 
mode. The results of these experiments are 
shown in Table III. 
Without derivatization, ll-OH-THC and THC-COOH could 
not be detected, and the sensitivity and chromatographic prop- 
erties of the other three compounds were not sufficient. 
The methylation is a preferred derivatization reaction for 
cannabinoids (37,39,41). The reaction with methyl iodide (MeI) 
in dimethyl sulfoxide (DMSO) and tetrabutylammonium 
hydroxide (TBAH) as phase transfer catalyst and ubsequent 
extraction with isooctane was not successful for CBD. Further- 
more, the detection limits of about 1 ng/mL for the other four 
compounds were not sufficient. Use of acetonitrile (ACN) or 
dimethylformamide (DMF) instead of DMSO and NaOH, K2CO3, 
or LiAIH4 instead of TBAH did not improve the results. Only in 
the reaction with MeI in NaOH/acetonitrile w re alI five com- 
pounds derivatized, but again with too small sensitivity. 
The experiments with trimethyloxonium tetrafuoroborate 
(Meerwein salt) as methylation agent in dichloromethane (44) 
were unsuccessful too. F r the application of this reagent, ex- 
tremely dry conditions are required, which obviously were not 
fulfilled in usual routine analysis. However, all five compounds 
were methylated by TMSH (0.2M in methanol) (41). With this 
reagent, he methylation ccurs at high temperature in the in- 
jector. Because this method is very convenient for routine mea- 
surements, some experiments for optimization were performed. 
As a result, he detection limits of 3 to 4 ng/mL were not suffi- 
cient, and for THC-COOH, four peaks possibly caused by in- 
complete or slow reaction f the OH and the COOH group of this 
compound appeared inthe chromatogram. Experiments to apply 
this reagent to the products of the MeI/TBAH in DMSO reaction 
in a two-step derivatization decreased the detectability of 11-OH- 
THC and THC-COOH and did not lead to the detection of CBD. 
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By combined alkylation and acylation with a mixture of 
pentafluoropropionic anhydride and pentafluoropropanol 
(PFPA/PFPOH) in analogy to the procedures described in liter- 
ature (38,40), all five substances were detected. However, THC 
and CBD gave the same peak of a monoacylated product and 
could not be distinguished in the chromatograms. Further- 
more, in contrast to literature data with GC-negative ion chem- 
ical ionization-MS (38), thesensitivity was not sufficient in our 
experiments u ing GC-EI-MS. 
Silylation is most frequently used for derivatization of
cannabinoids (33,35,36,42,45) because OH and COOH groups 
react equally well. Five different silylation reagents were tested: 
BSTFA, MTBSTFA, tri-i-propylsilanyl-diethylamine, phenyl- 
dimethylsilyl-diethylamine, a d i-propyl-dimethylsilyl-diethy- 
lamine (i-PrMe2Si-NEt2). The last three reagents were prepared 
from the corresponding chlorosilanes and diethylamine (45). 
Equally good results were obtained with BSTFA, MTBSTFA, 
and i-PrMe2Si-NEt2 for all five cannabinoids. Because of its 
higher stability and commercial vailability, BSTFA was chosen 
for the further experiments. This reaction was tested at dif- 
ferent temperatures, reaction times, and with different amounts 
of reagent. Best results were obtained with 20 IJL BSTFA after 
30 min at room temperature. Th  EI-mass spectra of the 
trimethylsilyl derivatives were in agreement with literature 
data (33), and the mass-to-charge ratios selected for the SIM de- 
tection are shown in Table I. 
Extraction. In the literature, liquid-liquid extraction 
(33,40-42) as well as SPE procedures (35-39) for analysis 
of cannabinoids from blood are described. Before xtraction, 
1 mL of the plasma sample was diluted with acetate buffer (pH 
4.0). This pH proved to be optimal because the extraction re- 
coveries of THC-COOH and of CBN from more basic solution 
(e.g., pH 6.0) decreased and the analytes are less stable in a more 
acidic solution. 
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methyl-t-butylether, ethyl acetate, 1-chlorobutane, and isooc- 
tane. Methyl-t-butylether and ethyl acetate were not suitable be- 
cause too many matrix components were extracted. On the
other hand, with the non-polar isooctane, THC-COOH was not 
sufficiently extracted. With 2 mL1-chlorobutane, all five com- 
pounds were extracted and the chromatograms were less dis- 
turbed by matrix components, but only medium or low 
extraction recoveries w re found: 43% THC, 59% 11-OH-THC, 
11% THC-COOH, 65% CBD, and 46% CBN. 
Therefore, an automatic SPE procedure with Chromabond 
C18 ec columns (200 mg C18-modified silica) at the extractor 
RapidTrace was chosen (see Materials and Methods section). 
The method recommended by Varian (46) was optimized with 
respect to the amount and composition of the wash solution (2 
mL 40% acetonitrile/H20) and the solvent for elution (1.8 mL 
acetonitrile). With this method, the extraction recoveries were 
between 43% and 95% (Table II), and the disturbance bymatrix 
components was sufficiently low. 
Validation of the method. The total procedure was validated 
according to the criteria of the Excel| program '~alistat" 
(43). The details are described n the Materials and Methods sec- 
tion, and the data are shown in Table II. With the exception of 
CBN, the LODs were between 0.15 and 0.29 ng/mL. The higher 
LOD of CBN (1.1 ng/mL) is caused by the lower extraction yield 
and by the use of the less intense CBN-TMS fragment m/z 310 
for quantification. Particularly at low concentrations, the most 
intense fragment (m/z 367) was disturbed y the matrix, and the 
calibration with m/z 382 was not sufficiently linear. 
A high intraday reproducibility was proven by the mean devi- 
ation of 1.8-3.9% (n = 384) between the two measurements of 
all samples of the clinical stu@. The interday reproducibility of 
the method was calculated from a control solution measured in 
each analysis series (standard deviation of 2.9-5.5%, n = 40). The 
apparent recovery of the five compounds (concentrations 10 
ng/mL) was between 95 and 104%. 
Altogether, the method proved to be suffi- 
ciently sensitive, accurate, and reproducible 
for the investigation ofplasma concentrations 




Figure 2. GC-MS-SIM chromatogram of a plasma sample ofa volunteer collected 60 min after 
application of a capsule with cannabis extract containing 10 mg THC and 5.4 mg CBD. The con- 
centrations in this sample were THC, 5.5 ng/mL; 11-OH-THC, 4.4 ng/mL; THC-COOH, 13 
ng/mL; and CBD, 2.3 ng/mL. CBN was not detected. 
Plasma concentrations after a single 
oral application of 10 mg THC and of 
cannabis extract containing 10 mg THC 
and 5.4 mg CBD 
In the double blind clinical study, plasma 
samples were obtained from each volunteer 
before and at eight different times after the 
application of a capsule with either placebo, 
10 mg THC or cannabis extract (10mg THC + 
5.4 mg CBD). Altogether 648 plasma samples 
were investigated, and each sample was ana- 
lyzed twice. A typical chromatogram of a 
plasma sample collected 60 min after applica- 
tion of a cannabis extract capsule is shown 
in Figure 2. THC, 11-OH-THC, THC-COOH, 
and CBD are clearly detected. CBN was not 
found in the samples. This was not only caused 
by the higher LOD of this compound because 
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it was shown by high-performance liquid chromatography 
that no essential amounts of this compound were present in 
Table IV. Maximum Concentrations (Cmax) of THC, 
11-OH-THC, THC-COOH, and CBD and Corresponding 
Time (tmax) After Administration* 
11-OH- THC- 
THC THC COOH CBD 
(n = 24) (n = 24) (n = 24) (n = 24) 
Administration of 10 mg THC 
Cmax(nS/mL)(range) 0.67-7.99 1.12-11.14 12.03-57.63 - 
Cma x (nglmL) (mean) 3.20 4.48 32.9 - 
tmax (min) (range) 30-183 30-190 67-235 - 
tmax (min) (mean) 63.6 90 124 - 
Detection time 240-360 360-540 > 1440 - 
after intake (min) 
Administration of cannabis extract containing 10 mg THC + 5.4 mg CBD 
Cmax(ng/mL)(range) 1.18-10.27 1.83-12.34 19.2-70.6 0.30-2.57 
Cmax (ng/mL) (mean) 4.05 4.88 35.46 0.95 
tmax (rain) (range) 33-125 37-130 65-230 30-120 
tma~ (min) (mean) 56 81.9 115 59.6 
Detection time 240-360 360-540 > 1440 180-240 
after intake (min) 
* Cr.ax: highest measured concentrations, tmax: estimated from the curves obtained 
by spline fitting to the measured points. 
the cannabis extract of he capsules. 
The maximum concentrations and the times (tm~x) at which 
these concentrations were attained are given in Table IV. The 
tmax values were estimated from the curves obtained by spline 
fitting to the measured points. Furthermore, the time periods 
for the detection of the compounds after intake are shown. 
The concentration versus time curves of THC and its metabo- 
lites 11-OH-THC and THC-COOH are characteristic for oral 
intake of the drug (4,14,16-19). Four typical examples are 
shown in Figure 3. In contrast to smoking, the concentrations 
of THC-COOH were from the beginning higher than that of 
THC. As a rule, after 1 h the concentrations of 11-OH-THC 
were also higher than those of THC, and this metabolite could 
be detected for a longer time than THC. 
But there is a large interindividual variation of heconcen- 
trations and ofthe concentration versus time curves. In most 
cases, the THC peak concentration was attained between 30 
and 60 rain after drug intake with a steady decrease after this 
time (Figure 3A). The maximum concentration of 11-OH-THC 
was about 15-30 min later and that of THC-COOH about 30-70 
rain later attained than that ofTHC. However, in a few cases, a 
delayed resorption was found with a non-detectable or very 
small THC concentration in the 30 and 60 rain samples and 
reaching the maximum 120 or 180 rain after drug intake 
(Figure 3C). In some other cases an intermittent resorption 
with a shoulder or a second maximum was observed (Figures 3B 
s] A lo 
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Figure 3. Plasma concentration versus time curves obtained after administration of a single capsule of cannabis extract containing 10 mg THC and 5.4 mg 
s optimal resorption (A), intermittent resorption wi h a second maximum for THC and 11-OH-THe (8); delayed onset resorption (s and shoulder for 
THC and 11-OH-THC and second maximum for THC-COOH (D). 
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Figure 4. Comparison of the concentration ratio 11-OH-THC/THC be- 
tween oral intake (this study, I0 mg THC) and smoking of a 1.75% or a 
3.55% marijuana cigarette [data from Huestis et al. (10)]. 
and 3D). The same irregularities were frequently seen in the 
curves of both metabolites and of CBD of the same volunteer. A 
similar variability of the resorption kinetics was already ob- 
served in a previous tudy of the authors (47). 
The rapid increase of the metabolite concentrations is caused 
by the extensive first-pass metabolism ofTHC, which is specific 
for oral intake. This is particularly the case for the primary 
metabolite 11-OH-THC. Therefore, the concentration ratio 11- 
OH-THC/THC could be a criterion for distinguishing between 
oral and inhalative drug consumption. This ratio is compared in
Figure 4 with the results obtained by Huestis et al. (10) in 
smoking experiments with 6 volunteers and joints containing 
1.75% and 3.5% THC over a period f6 h after consumption. As
expected, the ratio 11-OH-THC/THC increases for both kinds of 
drug use with time. However, the mean values of the oral ad- 
ministration are at all times by a factor of 3 to 4 higher than 
those of smoking. Despite th  large variation f the ratios within 
both groups, there is almost no overlapping of the data apart 
from some outliers. The same results were obtained for the 
cannabis extract administration. It can be concluded from the 
results given in Figure 4 that within the first 2 h after con- 
sumption, a ratio 11-OH-THC/THC > I and later than 2 h after 
consumption, a ratio 11-OH-THC/THC > 1.5 are strong indi- 
cations for oral intake of THC. The content of CBD in cannabis 
products varies in a wide range (21-23). The ratio of CBD/THC 
of 0.54 administrated in the present study is relatively high in 
comparison tothe confiscated samples described by E1Sohly et 
al. [mean 0.096 (22)]. Nevertheless, the dose of 5.4 mg CBD is 
in a range that can be assumed in cannabis abuse and particu- 
larly also in cannabis-based medicine xtracts (23). Data for 
CBD concentrations i  blood after controlled a ministration f 
this compound are rare. Ohlsson et al. (8) measured 37-61 
ng/mL (n = 3, mean 48.4 ng/mL) 1 h after intravenous injection 
of 20 mg and 3.0-17.8 ng/mL (n = 3, mean 10.2 ng/mL) 1 h 
after smoking of 19.2 mg deuterium-labeled CBD. Agurell et al. 
(30) found 1.1-11 ng/mL 1 h after oral application of 40 mg 
CBD (n = 12, mean 5.5 ng/mL) in chocolate cookies. The con- 
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centrations determined in the present study (0.30-2.57 ng/mL, 
mean 0.95 ng/mL 1 h after oral intake of 5.4 rag, see Table IV) 
are in agreement with these data. 
In this study, CBD was detectable between 3 and 4 h after 
administration. Generally, the detection of CBD should be 
favourable as an additional proof of cannabis exposure and for 
an improved interpretation f THC effects with consideration f 
the modifying interaction by CBD (23-25). 
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